Endovasc Ltd.
Technological advancements related to liposomes, stent coatings, and biodegradable/resorbable prostheses (stents) for the treatment of vascular dysfunction and heart disease.
The company was established in 1996 by Dr. David P. Summers to develop drugs for the treatment of endocrine, inflammatory and cardiovascular diseases. Endovasc’s subsidiary Angiogenix Ltd. holds the sublisence for an isomer of nicotine, which recruits the body’s owwn stem cells for angiogenesis in patients suffering from chronic myocardial ischemia. Liprostin Inc. retains the intellectual property for a liposomal based treatment that increases circulation, and reduces leg pain in patients with vascular diseases. Nutraceutical Development Corporation was established to commercialise its muscle mass enhancing product. And recently Endovasc announced the creation of a new subsidiary to showcase its promising ProStent technology with a patented stent coating comprised of a polymer and prostaglandin E1 (PGE1).
Diane Dottavio, Ph.D., President, CEO
Sam H. Lindsey, Jr., CFO and Chief Compliance Officer
Alan B. Lumsden, M.D.
Caroline E. Fife, M.D.
Craig J. Hartley, Ph.D.
Nathan Blumberg, M.D.
Yong-Jian Geng, M.D., Ph.D.
550 Club Drive, Suite 345
Montgomery, TX 77316
USA
Phone: +1-936-582-5920
The product portfolio of the company includes: Liprostin™ liposome-encapsulated form of prostaglandin E-1 (PGE-1), which has been approved by the FDA for treatment of ductus arteriosis of Botalli in neonates; potential in treating peripheral vascular disease who suffer pain from ischemic ulcers. PROStent™ is a stent coating comprising a polymer and prostaglandin E-1 (PGE-1). PGE-1 is released slowly, allowing the hormone to exert anti-inflammatory activity to down-regulate the immune response that occurs as a result of stenting Angiogenix™ is derived from the tobacco plant (purified nicotine) with potential beneficial effects on vascularisation.
The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.